Phase Ib/II Study of Neoadjuvant Pembrolizumab (MK-3475) with Gemcitabine-Cisplatin (cisplatin eligible) or Gemcitabine (cisplatin-ineligible) in Subjects with T2-4aN0M0 Urothelial Cancer
Study Overview
This is a pre-surgical study involving subjects with muscle invasive bladder cancer, or urothelial cancer, who are candidates for neoadjuvant therapy.
Study Description
This is a pre-surgical study involving subjects with muscle invasive bladder cancer, or urothelial cancer, who are candidates for neoadjuvant therapy.
Additional Information:
Participants will not be paid for their participation.
Research Study Identifier: TX5636
ClinicalTrials.gov Identifier: NCT1508602753 (GU14-188)
Principal Investigator:
Costantine Albany, MD
Currently Recruiting